Among HER2+ tumours, the analysis showed that clinical and pathological T stages (cpT-stage) were the only significant factors related to RFS (p = 0.048; p < 0.001, respectively) (Figure 3 and Figure 4). This evidence concerns the gene ERBB2 and neoplasm.